» Articles » PMID: 28921694

Protease Activated Receptor 2 Controls Myelin Development, Resiliency and Repair

Overview
Journal Glia
Specialty Neurology
Date 2017 Sep 19
PMID 28921694
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Oligodendrocytes are essential regulators of axonal energy homeostasis and electrical conduction and emerging target cells for restoration of neurological function. Here we investigate the role of protease activated receptor 2 (PAR2), a unique protease activated G protein-coupled receptor, in myelin development and repair using the spinal cord as a model. Results demonstrate that genetic deletion of PAR2 accelerates myelin production, including higher proteolipid protein (PLP) levels in the spinal cord at birth and higher levels of myelin basic protein and thickened myelin sheaths in adulthood. Enhancements in spinal cord myelin with PAR2 loss-of-function were accompanied by increased numbers of Olig2- and CC1-positive oligodendrocytes, as well as in levels of cyclic adenosine monophosphate (cAMP), and extracellular signal related kinase 1/2 (ERK1/2) signaling. Parallel promyelinating effects were observed after blocking PAR2 expression in purified oligodendrocyte cultures, whereas inhibiting adenylate cyclase reversed these effects. Conversely, PAR2 activation reduced PLP expression and this effect was prevented by brain derived neurotrophic factor (BDNF), a promyelinating growth factor that signals through cAMP. PAR2 knockout mice also showed improved myelin resiliency after traumatic spinal cord injury and an accelerated pattern of myelin regeneration after focal demyelination. These findings suggest that PAR2 is an important controller of myelin production and regeneration, both in the developing and adult spinal cord.

Citing Articles

A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases.

Khoon L, Piran R Int J Mol Sci. 2025; 26(1.

PMID: 39796264 PMC: 11722080. DOI: 10.3390/ijms26010410.


Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration.

Zhao J, Ren T, Li X, Guo T, Liu C, Wang X Front Cell Neurosci. 2022; 16:831977.

PMID: 35281298 PMC: 8913711. DOI: 10.3389/fncel.2022.831977.


Blocking Kallikrein 6 promotes developmental myelination.

Yoon H, Triplet E, Simon W, Choi C, Kleppe L, De Vita E Glia. 2021; 70(3):430-450.

PMID: 34626143 PMC: 8732303. DOI: 10.1002/glia.24100.


Critical Role of Astrocyte NAD Glycohydrolase in Myelin Injury and Regeneration.

Langley M, Choi C, Peclat T, Guo Y, Simon W, Yoon H J Neurosci. 2021; 41(41):8644-8667.

PMID: 34493542 PMC: 8513702. DOI: 10.1523/JNEUROSCI.2264-20.2021.


The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury.

Kim H, Triplet E, Radulovic M, Bouchal S, Kleppe L, Simon W Glia. 2021; 69(9):2111-2132.

PMID: 33887067 PMC: 8672305. DOI: 10.1002/glia.24012.


References
1.
Yoon H, Radulovic M, Wu J, Blaber S, Blaber M, Fehlings M . Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 2013; 127(2):283-98. PMC: 4097186. DOI: 10.1111/jnc.12293. View

2.
Raible D, McMorris F . Induction of oligodendrocyte differentiation by activators of adenylate cyclase. J Neurosci Res. 1990; 27(1):43-6. DOI: 10.1002/jnr.490270107. View

3.
Lohman R, Cotterell A, Suen J, Liu L, Do A, Vesey D . Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2011; 340(2):256-65. DOI: 10.1124/jpet.111.187062. View

4.
Barry G, Suen J, Le G, Cotterell A, Reid R, Fairlie D . Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010; 53(20):7428-40. DOI: 10.1021/jm100984y. View

5.
Irvine K, Blakemore W . Remyelination protects axons from demyelination-associated axon degeneration. Brain. 2008; 131(Pt 6):1464-77. DOI: 10.1093/brain/awn080. View